ClinicalTrials.gg
CompletedNCT00493246Updated Oct 21, 2016Results posted

Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients

A Phase 1 interventional study of IV Acetaminophen and IV Acetaminophen in Pain and Fever, sponsored by Mallinckrodt. Completed at 5 sites in United States. Open to participants aged 29 Days to 16 Years. Per ClinicalTrials.gov, last updated 2016-10-21.

Sponsored by Mallinckrodt · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
29 Days to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
83rd of 137
75 · median 95
Started
2007
with 7 others
Phase 1
11 of 137
none open now
Registered
17th of 137
by date
Lead sponsor
6 of 137
Mallinckrodt

Among the 137 studies testing acetaminophen in Pain, this one is the 83rd largest by enrollment, is one of 8 that started in 2007, is one of 11 in phase 1, and was the 17th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 29 Days to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

We are doing this study to find out what happens to acetaminophen in the body after it is given to children through the vein. Children's bodies may handle drugs differently than adults. Understanding how long the drug stays in the body and how the drug is changed or metabolized by the body (called pharmacokinetics) is an important step in learning what the best dose of acetaminophen for children should be. We are also interested in learning about the safety of this medication when given to children.

Read the detailed description

A Prospective, Multi-Center, Randomized, Open-Label, Single and Repeated Dose, 48 Hour Study, of Intravenous Acetaminophen in Pediatric Inpatients to Determine Pharmacokinetics (PK) and Safety in Acute Pain and Fever

03

Conditions studied

  • Pain
  • Fever

Browse trials for

04

Who can participate

Ages eligible
29 Days to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be eligible for entry into the Study, Subjects must meet or Subjects' Parent or Guardian must meet, agree with or confirm all of the following criteria:

  1. Provide written /Assent prior to participation in the Study
  2. Age strata:

    • Full-term Neonates (≤ 28 days old and minimum post conception age of 37 weeks at birth)
    • Infants [29 days to \<2 years (yrs) old]

      • 29 days to \<6 months
      • 6 to \<12 months
      • 12 to \<24 months)
    • Children (2 yrs to \<12 yrs old)
    • Adolescents (12 yrs to ≤16 yrs old)
  3. Inpatient status: are currently inpatients or have an admission scheduled and will soon become an inpatient (e.g., elective surgery)
  4. Diagnosis: requires or will require analgesic treatment for acute pain or antipyretic treatment for fever
  5. IV access: have a need for IV access for the duration of the Study either due to a nothing by mouth (NPO) status or due to the Investigator's assessment that oral treatment is not optimal (for example, severe nausea or vomiting)
  6. The Subject's Parent/Guardian must have the ability to read and understand the Study procedures and have the ability to communicate meaningfully with the Study Investigator and staff
  7. Be free of other physical, mental, or medical conditions which, in the opinion of the Investigator after completing the screening assessment, make Study participation inadvisable
  8. If a female of child bearing potential, have a negative pregnancy test

Exclusion Criteria (Screening)

A Subject is NOT eligible for entry if ANY of the following criteria are met:

  1. Is not able to comply with the plasma sampling requirements of the Study
  2. Has known or suspected to acetaminophen or the inactive of IV Acetaminophen.
  3. Has been taking any acetaminophen-containing product in the 12 hours prior or any of the following in the 48 hours prior to randomization in the Study: probenecid, disulfiram, isoniazide, St. John's wort, skullcap, chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, and valerian
  4. Has any significant medical condition that in the opinion of the Investigator contraindicates participation in the Study
  5. Has impaired liver function, with evidence of liver disease, or other condition that may suggest the potential for an increased susceptibility to hepatic toxicity with IV APAP exposure. For this criterion, a total greater than 1.5 times (ULN) for age or an (ALT) serum glutamic pyruvic transaminase (SGPT) or Aspartate transaminase (AST) serum glutamic oxaloacetic transaminase (SGOT) greater than 2.5 times ULN for age will be deemed as evidence of clinically significant ( [CTCAE] Grade 2) liver dysfunction or disease.
  6. Has significantly impaired renal function or known significant renal disease, as evidenced by an estimated (using the Schwartz formula) calculated to be less than 1/3rd of normal for the applicable age strata
  7. Has participated in another interventional clinical Study ( or marketed product) within 30 days of the planned Study randomization date
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Intravenous (IV) Acetaminophen 15 milligrams/kilogram (mg/kg)

    Intravenous Acetaminophen administered 15 milligrams/kilogram (mg/kg) every 8 hours (q8h) or every 6 hours (q6h) based age of subject

    Drug: IV Acetaminophen

  • Experimental
    Intravenous (IV) Acetaminophen 12.5 (mg/kg)

    Intravenous Acetaminophen administered 12.5 milligrams/kilogram (mg/kg) every 6 hours (q6h) or every 4 hours (q4h)

    Drug: IV Acetaminophen

Interventions

  • This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age) Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen

    Also known as: APAP, IV APAP

  • This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age) Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen

    Also known as: APAP, IV APAP

06

What researchers measure

Primary outcomes

  1. Single-dose Maximum Plasma Concentration (Cmax) , Micrograms Per Milliliter (µg/mL) Pharmacokinetics of IV Acetaminophen

    Cmax: Maximum Plasma Concentration

    Time frame: Time Zero (just prior to first dose) to 24 hours post first dose

  2. Single-dose Time to Reach Maximum Plasma Concentration [Tmax(h)] Pharmacokinetics of IV Acetaminophen

    Tmax: Time to reach maximum plasma concentration (Cmax)

    Time frame: Time Zero (just prior to first dose) to 24 hours post first dose

  3. Multiple-dose Area Und the Curve (AUC) From Time 0 (Predose) to the Time of the Dosing Interval at Steady-state (0-t (µg*h/ml) Pharmacokinetics of IV Acetaminophen

    AUC 0-t (µg\*h/ml): Area under the plasma concentration versus time curve from time 0 (predose) to the time of the dosing interval at steady-state.

    Time frame: Time Zero (just prior to first dose) to 48 hours post first dose

  4. Multiple-dose Terminal Elimination Half-life [t1/2(h)] Pharmacokinetics of IV Acetaminophen

    t1/2: Terminal elimination half-life

    Time frame: 48hrs

Secondary outcomes

  1. Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)

    A TEAE is defined as an adverse event that starts on or after the start of study medication

    Time frame: First dose of study medication to 30 days after the last dose of study medication

  2. Subjects Who Experience at Least One Serious Treatment-Emergent Adverse Event (TEAE)

    A Serious Treatment Emergent Adverse Event is defined as any untoward medical occurrence at any dose of IV acetaminophen that; Results in Death, Is life-threatening, Requires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is an important medical event

    Time frame: First dose to 30 days following last dose of study medication

07

Results

Posted Dec 29, 2010
Limitations and caveats
Median ranges were not calculated or not assessable for neonates at the following due to limited samples.: * 12.5 mg/kg q6h- t1/2 (h) * 15 mg/kg q8h -Cmax, Tmax, AUC0-t and t1/2.

Participant flow

The study was conducted at 5 sites in the US from 27 June 2007 to 01Sep 2008.

Participant flow — Overall Study
MilestoneNeonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen
Started2112139161210
Completed2112138151110
Not completed00001110
Withdrew: Withdrawal by subject00001000
Withdrew: No access to draw blood00000100
Withdrew: Lost to follow-up00000010

Outcome measures

PrimarySingle-dose Maximum Plasma Concentration (Cmax) , Micrograms Per Milliliter (µg/mL) Pharmacokinetics of IV Acetaminophen

Cmax: Maximum Plasma Concentration

Time frame:
Time Zero (just prior to first dose) to 24 hours post first dose
Reported as:
Median · micrograms per milliliter (µg/mL)
Single-dose Maximum Plasma Concentration (Cmax) , Micrograms Per Milliliter (µg/mL) Pharmacokinetics of IV Acetaminophen
micrograms per milliliter (µg/mL)Neonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen
Single-dose Maximum Plasma Concentration (Cmax) , Micrograms Per Milliliter (µg/mL) Pharmacokinetics of IV Acetaminophen40.1 (15.9 to 64.4)20.1 (20.1 to 20.1)16.7 (12.1 to 23.0)19.3 (16.2 to 25.4)18.2 (13.5 to 27.1)21.6 (14.4 to 60.8)15.9 (10.6 to 28.8)25.5 (9.91 to 49.8)
PrimarySingle-dose Time to Reach Maximum Plasma Concentration [Tmax(h)] Pharmacokinetics of IV Acetaminophen

Tmax: Time to reach maximum plasma concentration (Cmax)

Time frame:
Time Zero (just prior to first dose) to 24 hours post first dose
Reported as:
Median · Hour
Single-dose Time to Reach Maximum Plasma Concentration [Tmax(h)] Pharmacokinetics of IV Acetaminophen
HourNeonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen
Single-dose Time to Reach Maximum Plasma Concentration [Tmax(h)] Pharmacokinetics of IV Acetaminophen0.450 (0.400 to 0.500)0.333 (0.333 to 0.333)0.267 (0.000 to 0.383)0.267 (0.250 to 0.933)0.250 (0.0833 to 0.300)0.250 (0.0833 to 0.417)0.250 (0.0833 to 0.283)0.267 (0.00 to 0.333)
PrimaryMultiple-dose Area Und the Curve (AUC) From Time 0 (Predose) to the Time of the Dosing Interval at Steady-state (0-t (µg*h/ml) Pharmacokinetics of IV Acetaminophen

AUC 0-t (µg\*h/ml): Area under the plasma concentration versus time curve from time 0 (predose) to the time of the dosing interval at steady-state.

Time frame:
Time Zero (just prior to first dose) to 48 hours post first dose
Reported as:
Median · µg*h/ml
Multiple-dose Area Und the Curve (AUC) From Time 0 (Predose) to the Time of the Dosing Interval at Steady-state (0-t (µg*h/ml) Pharmacokinetics of IV Acetaminophen
µg*h/mlNeonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen
Multiple-dose Area Und the Curve (AUC) From Time 0 (Predose) to the Time of the Dosing Interval at Steady-state (0-t (µg*h/ml) Pharmacokinetics of IV Acetaminophen65.6 (55.8 to 75.4)105 (105 to 105)43.3 (9.15 to 79.2)51.9 (36.0 to 200)37.8 (11.3 to 52.3)48.0 (32.2 to 131)47.7 (22.4 to 132)64.0 (33.2 to 84.1)
PrimaryMultiple-dose Terminal Elimination Half-life [t1/2(h)] Pharmacokinetics of IV Acetaminophen

t1/2: Terminal elimination half-life

Time frame:
48hrs
Reported as:
Median · Hours
Multiple-dose Terminal Elimination Half-life [t1/2(h)] Pharmacokinetics of IV Acetaminophen
HoursNeonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen
Multiple-dose Terminal Elimination Half-life [t1/2(h)] Pharmacokinetics of IV Acetaminophen3.88 (3.88 to 3.88)—2.37 (1.15 to 2.81)2.79 (2.10 to 5.43)2.64 (2.24 to 4.46)2.77 (2.15 to 4.85)3.37 (2.69 to 4.16)4.10 (2.48 to 4.36)
SecondaryNumber of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)

A TEAE is defined as an adverse event that starts on or after the start of study medication

Time frame:
First dose of study medication to 30 days after the last dose of study medication
Reported as:
Number · Participants
Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsNeonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen
Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)21109211106
SecondarySubjects Who Experience at Least One Serious Treatment-Emergent Adverse Event (TEAE)

A Serious Treatment Emergent Adverse Event is defined as any untoward medical occurrence at any dose of IV acetaminophen that; Results in Death, Is life-threatening, Requires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is an important medical event

Time frame:
First dose to 30 days following last dose of study medication
Reported as:
Number · Participants
Subjects Who Experience at Least One Serious Treatment-Emergent Adverse Event (TEAE)
ParticipantsNeonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen
Subjects Who Experience at Least One Serious Treatment-Emergent Adverse Event (TEAE)00011211

Adverse events

Collected over Adverse Events and Serious Adverse Events were reported from the start of study medication to 30 days following the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Neonates:12.5 mg/kg Every 6 Hours (q6h) IV Acetaminophen—0/2 (0%)2/2 (100%)
Neonates: 15 mg/kg Every 8 Hours (q8h) IV Acetaminophen—0/1 (0%)1/1 (100%)
Infants: 12.5 mg/kg q4h IV Acetaminophen—0/12 (0%)10/12 (83.3%)
Infants:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen—1/13 (7.7%)7/13 (53.8%)
Children: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen—1/9 (11.1%)1/9 (11.1%)
Children: 15 mg/kg Every 6 Hours(q6h) IV Acetaminophen—2/16 (12.5%)10/16 (62.5%)
Adolescents: 12.5 mg/kg Every 4 Hours (q4h) IV Acetaminophen—1/12 (8.3%)10/12 (83.3%)
Adolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen—1/10 (10%)5/10 (50%)
Most frequent serious events
Most frequent serious events
EventNeonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen
Thoracic cavity drainage test abnormalInvestigations0/20/10/120/131/90/160/120/10
Abdominal PainGastrointestinal disorders0/20/10/120/130/90/160/121/10
Post procedural drainageSurgical and medical procedures0/20/10/120/130/90/161/120/10
ConvulsionNervous system disorders0/20/10/121/130/90/160/120/10
Mediastinal disorders chylothoraxRespiratory, thoracic and mediastinal disorders0/20/10/120/130/91/160/120/10
Wound infectionInfections and infestations0/20/10/120/130/91/160/120/10
Most frequent other events
Showing 10 of 33
Most frequent other events
EventNeonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV Acetaminophen
AtelectasisRespiratory, thoracic and mediastinal disorders1/21/11/122/130/93/161/120/10
Pulmonary EdemaRespiratory, thoracic and mediastinal disorders0/21/12/121/131/90/160/120/10
HypomagnesaemiaMetabolism and nutrition disorders1/20/13/121/130/91/161/121/10
Pleural EffusionRespiratory, thoracic and mediastinal disorders1/20/14/120/130/93/161/121/10
NauseaGastrointestinal disorders0/20/10/121/130/94/165/122/10
PruritisSkin and subcutaneous tissue disorders0/20/11/121/130/95/161/122/10
ConstipationGastrointestinal disorders0/20/10/122/130/91/162/120/10
HypokalemiaMetabolism and nutrition disorders0/20/12/121/131/92/160/121/10
StridorRespiratory, thoracic and mediastinal disorders0/20/12/121/130/90/160/120/10
WheezingRespiratory, thoracic and mediastinal disorders0/20/12/122/130/90/160/120/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Neonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenTotal
<=18 years211213916121075
Between 18 and 65 years000000000
>=65 years000000000
Sex: Female, Male
Sex: Female, Male(Participants)Neonates:12.5 mg/kg Every 6 Hours (q6h) IV AcetaminophenNeonates: 15 mg/kg Every 8 Hours (q8h) IV AcetaminophenInfants: 12.5 mg/kg q4h IV AcetaminophenInfants:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenChildren: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenChildren: 15 mg/kg Every 6 Hours(q6h) IV AcetaminophenAdolescents: 12.5 mg/kg Every 4 Hours (q4h) IV AcetaminophenAdolescents:15 mg/kg Every 6 Hours (q6h) IV AcetaminophenTotal
Female1147462631
Male108651010444
08

Study locations

5 sites
  • Lucile Packard Children's Hospital
    Stanford, California 94305, United States
  • CS Mott Childrens Hospital
    Ann Arbor, Michigan 48109, United States
  • Duke University Health Systems
    Durham, North Carolina 27710, United States
  • Children's Hospital Of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital Of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2007
First posted
Jun 28, 2007
Start
Jun 2007
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Dec 29, 2010
Last update
Oct 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00493246
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Jun 28, 2007
Start date
Jun 2007
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Dec 29, 2010
Last update
Oct 21, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion